Wikisage, the free encyclopedia of the second generation, is digital heritage
Perampanel: Difference between revisions
Jump to navigation
Jump to search
m (→ATC) |
No edit summary |
||
| Line 5: | Line 5: | ||
<ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf</ref> | <ref>http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf</ref> | ||
Perampanel was efficacious and well tolerated, despite the observation that the patient population exhibited characteristics of highly refractory epilepsy | |||
==ATC== | ==ATC== | ||
https://www.whocc.no/atc_ddd_index/?code=N03AX22 | https://www.whocc.no/atc_ddd_index/?code=N03AX22 | ||
Revision as of 19:41, 9 January 2018
(Fycompa) is an AED [1] 5′-(2-Cyanphenyl)-1′-phenyl-2,3′-bipyridinyl-6′(1′H)-on
[2] Perampanel was efficacious and well tolerated, despite the observation that the patient population exhibited characteristics of highly refractory epilepsy